Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Anaphylaxis is a medical situation in which severe allergic condition takes place which may leads to death of the patient. Itchy rash, throat swelling, shortness of breath, vomiting and low blood pressure are some of symptoms of anaphylaxis. Furthermore, it may lead to cardiovascular, respiratory, gastrointestinal and cutaneous manifestation which results in death of patients. Insect bites, unwanted food consumption and medication are common causes of anaphylactic reactions. It is generally diagnosed by the symptoms of the patients. Primary treatment of anaphylactic reactions is comprised of injection of epinephrine into the muscles then placing person with elevated feet to restore the normal blood flow.
The anaphylaxis treatment market is anticipated to grow at CAGR of 8.27% during the forecast period of 2022-2028. The rising incidences of anaphylaxis across the globe is propelling growth of anaphylaxis treatment market. The growing innovative and novel product launches by major companies is also refuelling growth of anaphylaxis treatment market. The government initiatives for cost reduction and rising number of product approvals is also driving growth of anaphylaxis treatment market. However, lack of awareness in developing regions and side effects due to elevated use of steroids and epinephrine is restraining growth of anaphylaxis treatment market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the anaphylaxis treatment market. In addition, complete analysis of changes on anaphylaxis treatment expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The pharmaceutical and biotechnology companies with collaboration of government across the globe are working for addressing the outbreak of COVID-19 from supporting development of vaccines to medicine supply chain challenges. Furthermore, generally used drugs such hydroxychloroquine have witnessed the tremendous rise in demand for the management of COVID-19. Owing to that the pharmaceutical and biotechnology companies have witnessed tremendous growth during the COVID-19 pandemic and it also impacting the anaphylaxis treatment market.
The anaphylaxis treatment market is segmented by allergy type, medication type, route of administration, distribution channel and geography.
The various allergy types such as food allergy, medication, insect stings, latex allergy and other such as mold, pet and pollen are comprised in the anaphylaxis treatment market. In which food allergy is likely to dominate the market in 2020. The food allergy is caused when immune system handling harmless protein in various foods as a threat and it releases various chemicals which triggers the different types of allergic reactions. Certain foods like peanuts, tree nuts, wheat, soy, fish, shellfish, eggs and milk may cause the food allergies.
The anaphylaxis treatment market is comprised of various medication type such as epinephrine, antihistamine, steroids, beta-agonist and others such as decongestant and leukotriene modifiers. In which epinephrine is estimated to dominate the market in 2020. The growing cases of food and other allergies owing to immunomodulation in many patients is propelling growth of anaphylaxis treatment market. The growing focus on early diseases treatment is also boosting growth of anaphylaxis treatment market.
The various routes of administration such as oral, parenteral and other are comprised in the anaphylaxis treatment market. In which parenteral segment is expected to dominate the market in 2020. The epinephrine is medication of choice for the first aid treatment of anaphylaxis. By vasoconstriction effect, it prevents or decreases upper airway mucosal edema, hypotension and shock. Furthermore, it have significant bronchodilator effects and cardiac inotropic and chronotropic effects.
The various distribution channel comprised in the anaphylaxis treatment market are hospital pharmacies, retail sales, drug store, mail order pharmacies and others. The hospital pharmacies is estimated to dominate the market in 2020. The rising patient footfall is propelling growth of anaphylaxis treatment market. The growing prevalence of allergic reactions is also driving growth of anaphylaxis treatment market.
The anaphylaxis treatment market is studied for key countries such as North America, Europe, Asia Pacific and Rest of the world. The North America is anticipated to dominate the market in 2020. The rising healthcare expenditure is propelling growth of anaphylaxis treatment market. The growing product launch and collaboration in major key players is also boosting growth of anaphylaxis treatment market. The rising immunomodulation in population is also fuelling growth of anaphylaxis treatment market.
The key competitors of this market include Amneal Pharmaceuticals Inc. (U.S.), Bioprojet (France), Mylan N.V. (U.S.), Adamis Pharmaceutical Corporation (San Diego), Abbott (U.S.), Pfizer Inc. (U.S.), Glaxosmithkline Plc., (U.K.), Merck And Co., Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel) and ALK-ABELLó (Denmark) among others.
July 2021: The GSK announced the FDA approval for Nucala for use in adults with chronic rhinosinusitis with nasal polyps. The Nucala is comprised of the mepolizumab which is a monoclonal antibody which targets interleukin-5 for treatment of patients with chronic rhinosinusitis with nasal polyps.
August 2018: Teva Pharmaceuticals announced that it got FDA approval for the launch of generic version of EpiPen and EpiPen Jr auto-injector for the emergency treatment of allergic reactions which comprises life threatening anaphylaxis in adults and pediatric patients.
July 2021: ALK-Abello A/s and Grandpharma Team up to market the first adrenaline autoinjector in China. The Jext is expected to be first AAI to market in China. Prior to registration in mainland and China, Grandpharma plans to start selling Jext in southern China under a special licence linked to the existing registration of Jext in Hong Kong.
The report analyses anaphylaxis treatment market based on the allergy type, medication type, route of administration, distribution channel and geography. By allergy type, the market is segmented into the food allergy, medication, insect stings, latex allergy and other such as mold, pet and pollen. Based on medication type, the market is segmented into epinephrine, antihistamine, steroids, beta-agonist and others such as decongestant and leukotriene modifiers. Based on route of administration, the market is segmented into oral, parenteral and other. By distribution channel, the market is segmented into the hospital pharmacies, retail sales, drug store, mail order pharmacies and others. The report also analyses the impact of COVID-19 on the anaphylaxis treatment market and it is analysed that The pharmaceutical and biotechnology companies with collaboration of government across the globe are working for addressing the outbreak of COVID-19 from supporting development of vaccines to medicine supply chain challenges. Furthermore, generally used drugs such hydroxychloroquine have witnessed the tremendous rise in demand for the management of COVID-19. Owing to that the pharmaceutical and biotechnology companies have witnessed tremendous growth during the COVID-19 pandemic and it also impacting the anaphylaxis treatment market. The reports also imparts major key players operating in the anaphylaxis treatment market.
Why to buy this report:
